No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SDGR240517C25000
- 0.12
- -0.06-33.33%
15min DelayClose May 9 15:59 ET
0.25High0.12Low
0.25Open0.18Pre Close16 Volume345 Open Interest25.00Strike Price337.00Turnover48.90%IV8.58%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.12Time Value100Contract SizeAmericanOptions Type0.1508Delta0.1418Gamma185.12Leverage Ratio-0.0251Theta0.0007Rho27.91Eff Leverage0.0079Vega
Intraday
- 5D
- 1D
News
Ansys Partners With Schrodinger to Accelerate Materials Development
Ansys (ANSS) said Tuesday it is collaborating with Schrodinger to develop an integrated computational materials engineering approach to product development that infuses virtual materials discovery int
Express News | Ansys And Schrödinger Collaborate To Develop ICME Approach
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Call Transcript
Maintaining Neutral: Assessing Schrodinger's Mixed Q1 Performance and Future Outlook
Express News | Citigroup Maintains Buy on Schrodinger, Lowers Price Target to $37
Schrodinger Gets Rights to Cancer Drug Candidate Back From Bristol
Comments
Read more
QianmengYu : nay, it means abandon. After IND, BMY doesn’t think this drug is promising and don’t want invest/bet even on phase 1. No more milestone payment (previous payment are not refundable).